Page de couverture de The Line

The Line

The Line

Auteur(s): Matt Gurney and Jen Gerson
Écouter gratuitement

The Line is a Canadian magazine dedicated to covering local, national and international politics, news, current events and occasionally some obscure stories. Hosted by Matt Gurney and Jen Gerson.

© 2026 The Line
Politique
Épisodes
  • Over the pump
    Jul 7 2026

    In this episode of On The Line, host Jen Gerson is joined by Andrew Leach, noted energy and environmental economist and professor of economics and law at the University of Alberta, for a conversation about Canadian energy policy at a pivotal moment.

    This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.

    A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don't routinely participate in research.

    So if you don’t live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians.

    A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more.

    Recorded on July 2, 2026, just ahead of two major pipeline announcements, the discussion doesn’t cover the specifics of the federal government’s decision to retrace the TMX route or the proposed Canadian Shield pipeline between Alberta and Sarnia. Instead, Gerson and Leach focus on the broader forces shaping Canada’s energy future.

    They discuss Prime Minister Mark Carney’s latest Forward Guidance video, the influence of the United States on Canadian energy policy and markets, the promise and limitations of carbon capture and storage, and the political significance of the new Memorandum of Understanding between Alberta and Ottawa. Throughout the conversation, Leach offers his perspective on what has changed — and what hasn’t — in the relationship between governments, industry, and the public.

    This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.

    That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.

    The playbook is written. Now Ottawa needs to deliver. Learn more at
    fpac.ca.

    The episode also asks a larger question: after decades of political conflict over pipelines, is Canada finally entering a new era? Could this be the beginning of a more grounded conversation about the country’s oil and gas sector, one that focuses less on symbolic battles and more on practical questions of economics, infrastructure, and national interest?

    This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.

    To learn more, visit ap1000.cameco.com.

    If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice. Be sure to check out our main page at ReadTheLine.ca.

    #OnTheLine #AndrewLeach #Energy #Pipelines #TMX #OilAndGas #MarkCarney #Alberta #CanadaPolitics #JenGerson

    Voir plus Voir moins
    58 min
  • Carney gets a pipeline deal. Now let's build the damn thing
    Jul 3 2026

    In the latest episode of The Line Podcast, recorded on July 3rd, 2026, Matt Gurney and Jen Gerson begin with the biggest political news of the week: a pipeline deal. Prime Minister Mark Carney has struck agreements with both Alberta and British Columbia to move another pipeline project forward. Your hosts discuss the proposed route, which closely follows the existing Trans Mountain corridor, the political wheeling and dealing that made the agreement possible, and what it could mean for Alberta’s upcoming referendum. Matt also can’t help asking an obvious question: since this was always the logical outcome, why did it take so long? Was there a genuine engineering obstacle behind the scenes, or are Canadian governments simply incapable of moving quickly?

    This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.

    Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.

    Find them Fractional-Execs.ca.

    Next, they turn to another round of comments from U.S. Ambassador Pete Hoekstra. After a brief discussion of CUSMA, the conversation shifts to Hoekstra’s remarks about the Gordie Howe International Bridge. Your hosts aren’t especially worried. In fact, they think they have the perfect strategy: troll the White House until it becomes so embarrassed that it can’t wait to open the bridge just to make the pain stop. Their suggestions include live episodes of The View from the bridge deck, Bruce Springsteen concerts, and, naturally, renaming it the Barack Hussein Obama Nobel Peace Prize Bridge of Friendship.

    This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the US FDA and other major jurisdictions. To submit a complete CTA, applicants need to provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it’s safe to administer to trial participants. This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they’ve gotten 16 therapies to trial. To learn more, visit BioCanRx.com.


    Finally, Matt attempts to diagnose what has gone wrong with Canada’s civic culture and even ventures a possible cure. Toronto, he argues, needs its own version of the Calgary Stampede, and Canada more broadly needs something capable of genuinely uniting the country. The trouble is that neither host can think of an obvious candidate. They conclude that Canada — and Toronto in particular — has become too self-conscious and too embarrassed by its own past to celebrate it with much enthusiasm.

    All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca.

    #TheLinePodcast
    #MarkCarney
    #PipelinePolitics
    #CanadianPolitics
    #CanadaUSRelations
    #CUSMA
    #GordieHoweBridge
    #AlbertaPolitics
    #PoliticalAnalysis
    #CurrentAffairs

    Voir plus Voir moins
    1 h et 19 min
  • Frontlines of Canadian Emergency Care
    Jun 30 2026
    In this episode of On The Line, host Matt Gurney sits down with Dr. Brian Goldman, veteran emergency physician at Mount Sinai Hospital in Toronto and author of The Casino Shift: Stories from an ER on the Edge, for a candid conversation about the state of emergency medicine in Canada. (You can find it on Indigo's website, or, if you prefer, on Amazon.)This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. It’s up to the developer of the drug to decide whether they want to trial it in Canada –– and many do. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the U.S. FDA and other major jurisdictions. If they approve, and if the trial receives research ethics approval, it can start enrolling Canadian patients. To submit a complete CTA, applicants must provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it’s safe to administer to trial participants.This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real-world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they’ve gotten 16 therapies to trial.But once a trial starts, how can Canadians learn about it, and where can they access it? That question and more next time. Visit BioCanRx.com to learn more.Drawing on decades in one of the country’s busiest emergency departments, Goldman explains why today’s ERs are under extraordinary strain, and why the problems extend far beyond long wait times. They discuss the pressures facing doctors, nurses, and patients alike, the growing mismatch between demand and capacity, and why the old problem of hallway medicine is increasingly giving way to something even worse: chair medicine, with patients waiting for hours in chairs because there simply isn’t anywhere else to put them.The conversation also explores the human side of emergency medicine. Goldman reflects on the emotional and psychological toll of working in an overwhelmed system, the stories that inspired The Casino Shift, and what keeps health-care workers coming back despite the mounting pressures.This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry can help build Canada strong. We need more homes, faster and more affordably, and Canadian wood can be part of the solution. Light-frame construction, mass timber, modular systems, and other modern building methods can support housing, lower embodied carbon, and strengthen domestic supply chains. The same opportunity exists in schools, health facilities, community buildings, and public infrastructure. When Canada builds, Canadian materials and Canadian workers must be part of the plan. Learn more at fpac.ca.Finally, Matt and Goldman tackle one of the most contentious questions in Canadian health care. Goldman argues that it’s time for a calm, respectful, and evidence-based discussion about whether private options should play a larger role within Canada’s publicly funded system. Rather than treating the issue as ideological warfare, he makes the case for focusing on what actually improves patient care, and how other jurisdictions are approaching this problem.It’s a frank discussion about the realities facing Canada’s healthcare system, the people trying to hold it together, and the difficult choices that may lie ahead.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice, and check out our main page at ReadTheLine.ca.#OnTheLine #BrianGoldman #Healthcare #EmergencyMedicine #CanadianHealthcare #MountSinai #TheCasinoShift #PublicHealth #CanadaPolitics #MattGurney
    Voir plus Voir moins
    1 h et 1 min
adbl_web_anon_alc_button_suppression_t1
Pas encore de commentaire